Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.63 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420336 | 0.86 | SLC6A9 (0.65) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4433416 | 0.84 | SLC6A9 (0.65) | SLC6A9KCNH2GPR119 | |
| SCHEMBL4419994 | 0.79 | SLC6A9 (0.64) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4425015 | 0.78 | SLC6A9 (0.77) | SLC6A9GPR55KCNH2 | |
| SCHEMBL3923127 | 0.78 | SLC6A9 (0.98) | SLC6A9GPR55KCNH2 | |
| SCHEMBL3920651 | 0.77 | SLC6A9 (1.00) | SLC6A9GPR55 | |
| SCHEMBL3919841 | 0.77 | SLC6A9 (0.76) | SLC6A9GPR55KCNH2 | |
| SCHEMBL5037826 | 0.77 | SLC6A9 (0.71) | SLC6A9GPR55KCNH2 | |
| SCHEMBL4138706 | 0.76 | SLC6A9 (0.59) | SLC6A9GPR55 | |
| SCHEMBL3930029 | 0.76 | SLC6A9 (0.88) | SLC6A9GPR55KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885GPR55 170/4885KCNH2 719/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | SLC6A9 82/4885GPR55 170/4885KCNH2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.